when was glp 1 discovered Evolution of GLP‐1 Receptor Agonists for Diabetes Treatment Design and discovery of a

The FDA has approved GLP-1 receptor agonists for type 2 diabetes management, with select agents (semaglutide/Wegovy and liraglutide/Saxenda) also approved for chronic weight management in adults with BMI 30 kg/m or 27 kg/m with at least one weight-related comorbidity

These elements establish a feedback loop that delays tissue repair, making it essential to precisely regulate the localized microenvironment to address multiple pathogenic mechanisms simultaneously

Together, we can transform genetic risk into genetic resilience

Unlike surgery, which physically limits stomach capacity, GLP-1 drugs work through chemical signaling that stops the moment you stop taking them